Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Human-derived mesenchymal stem cell conditioned medium for heart failure
jRCT1051220088Recruiting
- Sponsor
- Seihoku Clinic
- Start
- Aug 2022
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label, single-arm trial of human-derived mesenchymal stem cell conditioned medium in heart failure (HF), sponsored by Seihoku Clinic. Primary endpoints: NT-proBNP change, High-sensitivity C-reactive protein change and 8 more. Started Aug 2022; status: recruiting.
02
Drugs
human-derived mesenchymal stem cell conditioned medium
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on jRCT1051220088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051220088.